Gedeon Richter to Buy Mayne Pharma for A$604 Million, Nearly Double Its Last Close

A unanimous board and lined-up holders give the Hungarian buyer a clear first path, if regulators and a prior sale cooperate.

Sources

Sources & evidence

What “Source checked” means

Mayne Pharma has agreed to be bought by Hungary's Gedeon Richter for A$6.40 a share in cash, the Australian drugmaker said Tuesday.

Mayne Pharma announced the scheme on Tuesday in Australia, which was Monday evening in the United States. The buyer is Gedeon Richter, a Hungarian drugmaker listed in Budapest.

Under a scheme implementation deed, Richter would acquire every Mayne share through a new Australian subsidiary. A scheme of arrangement is a court-supervised takeover voted on by shareholders.

A price near double the last close

Richter will pay A$6.40 in cash for each Mayne share. The price values Mayne's equity at about A$604 million.

Reuters converted that value to $407.76 million, at a rate of $1 to A$1.4813. Every other amount in this article is in Australian dollars.

The offer is a 99.4% premium to Mayne's close on Monday, November 16. TickerGrove calculates that the implied closing price was about A$3.21 a share.

It also stands 124% above the 30-day volume-weighted average price, or VWAP. The premiums are 122% over 90 days and 145% over 180 days.

In intraday trading on Tuesday, Mayne shares jumped 86% to A$5.97, a one-year high. Reuters said the stock was on track for its best session on record if the gains held.

That intraday price is not a settled close. It still sat A$0.43 below the offer, a gap of about 6.7%, both TickerGrove calculations.

Unanimous board, a fifth of the register lined up

Mayne's board unanimously recommends the scheme, in the absence of a superior proposal. The support is subject to an independent expert concluding the scheme is in shareholders' best interests.

“The Board’s priority throughout has been to maximise value and certainty for all shareholders,” Chair Bruce Robinson said.

Three large holders have indicated support on the same terms. Funicular Funds holds 9.82%, Bruce Mathieson 6.46% and Trium Capital 5.85%.

Together they hold 22.14% of Mayne's ordinary shares, the announcement said.

No financing condition, several approval conditions

Richter will finance the deal entirely from its internal cash resources. The scheme therefore carries no financing condition.

Completion first requires Mayne to finish selling its International business to Evaris Pharma. That sale is itself a condition of the scheme.

Richter also needs clearance from Australia's Foreign Investment Review Board, known as FIRB. United States antitrust clearance is also required.

Shareholders must approve the scheme, and Australian courts must approve it too. The deal must also avoid specified adverse changes and prescribed occurrences.

Mayne accepted exclusivity restrictions, and Richter holds matching rights over qualifying rival proposals, subject to fiduciary exceptions. A break fee of A$6 million and a matching reverse fee apply in specified circumstances.

Why Richter wants Mayne's U.S. business

Mayne makes branded and generic drugs focused on women's health, dermatology and infectious diseases. After the International sale, its business is focused on the United States.

“Mayne’s existing portfolio – including our estetrol-based innovative combination contraceptive pill – and its commercial footprint provide a strong base to build on,” Deputy Chief Executive László Kovács said.

Kovács said the base would help Richter bring new women's-health treatments to the United States. Richter operates in about 50 countries.

Mayne's U.S. platform includes DistributeRx, a direct-to-patient service launched in March 2026. Women's health and dermatology are its stated growth focus.

The Evaris sale that has to close first

On November 6, Mayne agreed to sell Mayne Pharma International to Evaris Pharma for A$55.5 million in cash. The binding sale was announced to the ASX, Australia's main exchange.

The unit's fiscal 2026 revenue was A$70.7 million, the announcement said. It includes contract manufacturing and the Salisbury facility in South Australia.

The Evaris sale needs approval from the Australian Competition and Consumer Commission, or ACCC. It does not need FIRB approval, and completion is expected in the third quarter of fiscal 2027.

A cleaner ending than the Cosette saga

The Richter deal follows a failed pursuit by Cosette Pharmaceuticals of the United States. Cosette agreed in February 2025 to pay A$7.40 a share, valuing Mayne at A$672 million.

Cosette later sought to walk away, citing a material adverse change in Mayne's business. Australia then blocked the deal last year on national-interest grounds.

Cosette had threatened to shut Mayne's Adelaide plant, which employs about 200 people. The plant is one of Mayne's two main factories.

By Monday's close, Mayne shares had lost more than half their value since Cosette's offer was first announced. The Richter premium is measured against that reduced base.

What remains unknown

Whether the independent expert concludes the scheme is in shareholders' best interests is unknown. The board's recommendation depends on that conclusion holding.

Whether FIRB and United States antitrust regulators clear the acquisition is not yet known. The Evaris sale must also clear the ACCC and complete.

Whether a superior proposal emerges is unknown. Richter's matching rights would shape how Mayne could respond to one.

The approvals that come next

What to watch: the scheme booklet and independent expert's report, expected in mid-December 2026. They follow a first court hearing.

Shareholders are provisionally due to vote in late January 2027. A second court hearing and implementation are targeted for mid-to-late March 2027.

The intraday share price is the live test until then. A wider gap to A$6.40 would signal growing doubt about completion.

Sources & evidence

Source checked3 sources · 15 figures

Figure receipts

Every figure in this article, with the source it came from.

  • $6.40 Gedeon Richter offer price for Mayne Pharma shares

    As of Nov. 16, 2026

  • $604M Mayne Pharma equity value under the Richter scheme

    As of Nov. 16, 2026

  • 99.4 Richter offer premium to Mayne's November 16, 2026 close

    As of Nov. 16, 2026

  • 124 Richter offer premium to Mayne's 30-day VWAP

    As of Nov. 16, 2026

  • $3.21 Mayne Pharma implied closing price, November 16, 2026 (calculation)

    As of Nov. 16, 2026

  • 94.4 Mayne Pharma shares assumed in the scheme equity value

    As of Nov. 16, 2026

  • 22.14 Mayne Pharma shareholder support indicated for the scheme

    As of Nov. 16, 2026

  • $6M Mayne Pharma scheme break fee

    As of Nov. 16, 2026

  • $55.5M Evaris Pharma consideration for Mayne Pharma International

    As of Nov. 16, 2026

  • $70.7M Mayne Pharma International revenue, fiscal 2026

    As of Nov. 16, 2026

  • $407.76M Mayne Pharma equity value in U.S. dollars (Reuters conversion)

    As of Nov. 16, 2026

  • 86 Mayne Pharma share-price move, intraday Tuesday November 17, 2026 (ASX)

    As of Nov. 16, 2026

  • $5.97 Mayne Pharma last traded price, intraday Tuesday November 17, 2026 (ASX)

    As of Nov. 16, 2026

  • $7.40 Cosette Pharmaceuticals offer price for Mayne Pharma shares, February 2025

    As of Nov. 16, 2026

  • $672M Cosette Pharmaceuticals offer value for Mayne Pharma, February 2025

    As of Nov. 16, 2026

As of Monday, Nov. 16, 2026 (Tuesday, Nov. 17 in Australia).

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories